The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses
Abstract The capacity of an adjuvant to reduce the amount of antigen required in vaccines would be beneficial in a variety of settings, including situations where antigen is difficult or expensive to manufacture, or in situations where demand exceeds production capacity, such as pandemic influenza....
Gespeichert in:
| Veröffentlicht in: | Vaccine 2007-03, Vol.25 (14), p.2541-2544 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2544 |
|---|---|
| container_issue | 14 |
| container_start_page | 2541 |
| container_title | Vaccine |
| container_volume | 25 |
| creator | Boyle, Jeff Eastman, Donna Millar, Christine Camuglia, Sarina Cox, John Pearse, Martin Good, Jeremy Drane, Debbie |
| description | Abstract The capacity of an adjuvant to reduce the amount of antigen required in vaccines would be beneficial in a variety of settings, including situations where antigen is difficult or expensive to manufacture, or in situations where demand exceeds production capacity, such as pandemic influenza. The ability to reduce antigen dose would also be a significant advantage in combination vaccines, and vaccines that by necessity must contain multiple antigens to accommodate variability between strains or genotypes. ISCOMATRIX™ adjuvant was compared to aluminium hydroxide adjuvant (Al(OH3 )) for induction of antibody responses and dose sparing of a recombinant HIV gp120 vaccine. Neutralising antibody responses were significantly greater, at the same protein dose, when the gp120 protein was formulated with ISCOMATRIX™ adjuvant compared to Al(OH3 ). Moreover, strong responses were achieved with up to 100-fold lower doses of gp120 using ISCOMATRIX™ adjuvant. Therefore, ISCOMATRIX™ adjuvant has the potential to substantially reduce the dose of antigen required in human vaccines, without compromising the immune response. |
| doi_str_mv | 10.1016/j.vaccine.2006.12.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70288182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X0601348X</els_id><sourcerecordid>3379246201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-f157859ac28f7fd90df1e47a63a2f4eaa412dfb82e861522e07ece92cf7b79823</originalsourceid><addsrcrecordid>eNqNks9qGzEQxpfS0jhpH6FlobQ3bzXa1Up7aQmmfwwpgcYF34SsHaVy15Ij7Rp8z5P00fokleMFQy7tSTDz-0Yz802WvQJSAIH6_brYKa2tw4ISUhdACwLiSTYBwcspZSCeZhNC62paAVmeZecxrgkhrITmeXYGnFakamCSbRY_MR9629l-n3uTz29m198uF9_nyz_3v3PVroedcn1ufMhbHzEP2A66t94d4JSxt-gesmM3MRF3gw3W3T6kV77dp1DcehcxvsieGdVFfDm-F9mPz58Ws6_Tq-sv89nl1VQzwvupAcYFa5SmwnDTNqQ1gBVXdamoqVCpCmhrVoKiqIFRioSjxoZqw1e8EbS8yN4d626Dvxsw9nJjo8auUw79ECUnVAj4D5CSEipOeQLfPALXfgguDSGBVRxqxghJFDtSOvgYAxq5DXajwl4CkQfb5FqOi5IH2yRQmWxLutdj9WG1wfakGn1KwNsRUFGrzgTltI0nTtTJ6pIl7uORw7TdncUgo7boNLY2oO5l6-0_W_nwqILurLPp01-4x3iaWsYkkDeHGzucGKkJlJVYln8BTenObQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547165500</pqid></control><display><type>article</type><title>The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Boyle, Jeff ; Eastman, Donna ; Millar, Christine ; Camuglia, Sarina ; Cox, John ; Pearse, Martin ; Good, Jeremy ; Drane, Debbie</creator><creatorcontrib>Boyle, Jeff ; Eastman, Donna ; Millar, Christine ; Camuglia, Sarina ; Cox, John ; Pearse, Martin ; Good, Jeremy ; Drane, Debbie</creatorcontrib><description>Abstract The capacity of an adjuvant to reduce the amount of antigen required in vaccines would be beneficial in a variety of settings, including situations where antigen is difficult or expensive to manufacture, or in situations where demand exceeds production capacity, such as pandemic influenza. The ability to reduce antigen dose would also be a significant advantage in combination vaccines, and vaccines that by necessity must contain multiple antigens to accommodate variability between strains or genotypes. ISCOMATRIX™ adjuvant was compared to aluminium hydroxide adjuvant (Al(OH3 )) for induction of antibody responses and dose sparing of a recombinant HIV gp120 vaccine. Neutralising antibody responses were significantly greater, at the same protein dose, when the gp120 protein was formulated with ISCOMATRIX™ adjuvant compared to Al(OH3 ). Moreover, strong responses were achieved with up to 100-fold lower doses of gp120 using ISCOMATRIX™ adjuvant. Therefore, ISCOMATRIX™ adjuvant has the potential to substantially reduce the dose of antigen required in human vaccines, without compromising the immune response.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2006.12.018</identifier><identifier>PMID: 17240491</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject><![CDATA[Adjuvants, Immunologic - administration & dosage ; AIDS Vaccines - administration & dosage ; AIDS Vaccines - immunology ; Allergy and Immunology ; Aluminum ; Animals ; Applied microbiology ; Biological and medical sciences ; Cancer ; Chemotherapy ; CHO Cells ; Cholesterol - administration & dosage ; Cricetinae ; Cricetulus ; Dose-Response Relationship, Immunologic ; Drug Combinations ; Fundamental and applied biological sciences. Psychology ; Genotypes ; gp120 ; Guinea Pigs ; HIV ; HIV Antibodies - blood ; HIV Envelope Protein gp120 - immunology ; Human immunodeficiency virus ; Human papillomavirus ; Immune response ; Influenza ; ISCOMATRIX™ adjuvant ; Lymphocytes ; Microbiology ; Miscellaneous ; Phospholipids - administration & dosage ; Production capacity ; Proteins ; Public health ; Rodents ; Saponins - administration & dosage ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Synthetic - administration & dosage ; Virology]]></subject><ispartof>Vaccine, 2007-03, Vol.25 (14), p.2541-2544</ispartof><rights>Elsevier Ltd</rights><rights>2006 Elsevier Ltd</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Elsevier Limited Mar 30, 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-f157859ac28f7fd90df1e47a63a2f4eaa412dfb82e861522e07ece92cf7b79823</citedby><cites>FETCH-LOGICAL-c507t-f157859ac28f7fd90df1e47a63a2f4eaa412dfb82e861522e07ece92cf7b79823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1547165500?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18626435$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17240491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boyle, Jeff</creatorcontrib><creatorcontrib>Eastman, Donna</creatorcontrib><creatorcontrib>Millar, Christine</creatorcontrib><creatorcontrib>Camuglia, Sarina</creatorcontrib><creatorcontrib>Cox, John</creatorcontrib><creatorcontrib>Pearse, Martin</creatorcontrib><creatorcontrib>Good, Jeremy</creatorcontrib><creatorcontrib>Drane, Debbie</creatorcontrib><title>The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract The capacity of an adjuvant to reduce the amount of antigen required in vaccines would be beneficial in a variety of settings, including situations where antigen is difficult or expensive to manufacture, or in situations where demand exceeds production capacity, such as pandemic influenza. The ability to reduce antigen dose would also be a significant advantage in combination vaccines, and vaccines that by necessity must contain multiple antigens to accommodate variability between strains or genotypes. ISCOMATRIX™ adjuvant was compared to aluminium hydroxide adjuvant (Al(OH3 )) for induction of antibody responses and dose sparing of a recombinant HIV gp120 vaccine. Neutralising antibody responses were significantly greater, at the same protein dose, when the gp120 protein was formulated with ISCOMATRIX™ adjuvant compared to Al(OH3 ). Moreover, strong responses were achieved with up to 100-fold lower doses of gp120 using ISCOMATRIX™ adjuvant. Therefore, ISCOMATRIX™ adjuvant has the potential to substantially reduce the dose of antigen required in human vaccines, without compromising the immune response.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>AIDS Vaccines - administration & dosage</subject><subject>AIDS Vaccines - immunology</subject><subject>Allergy and Immunology</subject><subject>Aluminum</subject><subject>Animals</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>CHO Cells</subject><subject>Cholesterol - administration & dosage</subject><subject>Cricetinae</subject><subject>Cricetulus</subject><subject>Dose-Response Relationship, Immunologic</subject><subject>Drug Combinations</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genotypes</subject><subject>gp120</subject><subject>Guinea Pigs</subject><subject>HIV</subject><subject>HIV Antibodies - blood</subject><subject>HIV Envelope Protein gp120 - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Human papillomavirus</subject><subject>Immune response</subject><subject>Influenza</subject><subject>ISCOMATRIX™ adjuvant</subject><subject>Lymphocytes</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Phospholipids - administration & dosage</subject><subject>Production capacity</subject><subject>Proteins</subject><subject>Public health</subject><subject>Rodents</subject><subject>Saponins - administration & dosage</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Synthetic - administration & dosage</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNks9qGzEQxpfS0jhpH6FlobQ3bzXa1Up7aQmmfwwpgcYF34SsHaVy15Ij7Rp8z5P00fokleMFQy7tSTDz-0Yz802WvQJSAIH6_brYKa2tw4ISUhdACwLiSTYBwcspZSCeZhNC62paAVmeZecxrgkhrITmeXYGnFakamCSbRY_MR9629l-n3uTz29m198uF9_nyz_3v3PVroedcn1ufMhbHzEP2A66t94d4JSxt-gesmM3MRF3gw3W3T6kV77dp1DcehcxvsieGdVFfDm-F9mPz58Ws6_Tq-sv89nl1VQzwvupAcYFa5SmwnDTNqQ1gBVXdamoqVCpCmhrVoKiqIFRioSjxoZqw1e8EbS8yN4d626Dvxsw9nJjo8auUw79ECUnVAj4D5CSEipOeQLfPALXfgguDSGBVRxqxghJFDtSOvgYAxq5DXajwl4CkQfb5FqOi5IH2yRQmWxLutdj9WG1wfakGn1KwNsRUFGrzgTltI0nTtTJ6pIl7uORw7TdncUgo7boNLY2oO5l6-0_W_nwqILurLPp01-4x3iaWsYkkDeHGzucGKkJlJVYln8BTenObQ</recordid><startdate>20070330</startdate><enddate>20070330</enddate><creator>Boyle, Jeff</creator><creator>Eastman, Donna</creator><creator>Millar, Christine</creator><creator>Camuglia, Sarina</creator><creator>Cox, John</creator><creator>Pearse, Martin</creator><creator>Good, Jeremy</creator><creator>Drane, Debbie</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20070330</creationdate><title>The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses</title><author>Boyle, Jeff ; Eastman, Donna ; Millar, Christine ; Camuglia, Sarina ; Cox, John ; Pearse, Martin ; Good, Jeremy ; Drane, Debbie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-f157859ac28f7fd90df1e47a63a2f4eaa412dfb82e861522e07ece92cf7b79823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>AIDS Vaccines - administration & dosage</topic><topic>AIDS Vaccines - immunology</topic><topic>Allergy and Immunology</topic><topic>Aluminum</topic><topic>Animals</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>CHO Cells</topic><topic>Cholesterol - administration & dosage</topic><topic>Cricetinae</topic><topic>Cricetulus</topic><topic>Dose-Response Relationship, Immunologic</topic><topic>Drug Combinations</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genotypes</topic><topic>gp120</topic><topic>Guinea Pigs</topic><topic>HIV</topic><topic>HIV Antibodies - blood</topic><topic>HIV Envelope Protein gp120 - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Human papillomavirus</topic><topic>Immune response</topic><topic>Influenza</topic><topic>ISCOMATRIX™ adjuvant</topic><topic>Lymphocytes</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Phospholipids - administration & dosage</topic><topic>Production capacity</topic><topic>Proteins</topic><topic>Public health</topic><topic>Rodents</topic><topic>Saponins - administration & dosage</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Synthetic - administration & dosage</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boyle, Jeff</creatorcontrib><creatorcontrib>Eastman, Donna</creatorcontrib><creatorcontrib>Millar, Christine</creatorcontrib><creatorcontrib>Camuglia, Sarina</creatorcontrib><creatorcontrib>Cox, John</creatorcontrib><creatorcontrib>Pearse, Martin</creatorcontrib><creatorcontrib>Good, Jeremy</creatorcontrib><creatorcontrib>Drane, Debbie</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boyle, Jeff</au><au>Eastman, Donna</au><au>Millar, Christine</au><au>Camuglia, Sarina</au><au>Cox, John</au><au>Pearse, Martin</au><au>Good, Jeremy</au><au>Drane, Debbie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2007-03-30</date><risdate>2007</risdate><volume>25</volume><issue>14</issue><spage>2541</spage><epage>2544</epage><pages>2541-2544</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract The capacity of an adjuvant to reduce the amount of antigen required in vaccines would be beneficial in a variety of settings, including situations where antigen is difficult or expensive to manufacture, or in situations where demand exceeds production capacity, such as pandemic influenza. The ability to reduce antigen dose would also be a significant advantage in combination vaccines, and vaccines that by necessity must contain multiple antigens to accommodate variability between strains or genotypes. ISCOMATRIX™ adjuvant was compared to aluminium hydroxide adjuvant (Al(OH3 )) for induction of antibody responses and dose sparing of a recombinant HIV gp120 vaccine. Neutralising antibody responses were significantly greater, at the same protein dose, when the gp120 protein was formulated with ISCOMATRIX™ adjuvant compared to Al(OH3 ). Moreover, strong responses were achieved with up to 100-fold lower doses of gp120 using ISCOMATRIX™ adjuvant. Therefore, ISCOMATRIX™ adjuvant has the potential to substantially reduce the dose of antigen required in human vaccines, without compromising the immune response.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>17240491</pmid><doi>10.1016/j.vaccine.2006.12.018</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2007-03, Vol.25 (14), p.2541-2544 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70288182 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Adjuvants, Immunologic - administration & dosage AIDS Vaccines - administration & dosage AIDS Vaccines - immunology Allergy and Immunology Aluminum Animals Applied microbiology Biological and medical sciences Cancer Chemotherapy CHO Cells Cholesterol - administration & dosage Cricetinae Cricetulus Dose-Response Relationship, Immunologic Drug Combinations Fundamental and applied biological sciences. Psychology Genotypes gp120 Guinea Pigs HIV HIV Antibodies - blood HIV Envelope Protein gp120 - immunology Human immunodeficiency virus Human papillomavirus Immune response Influenza ISCOMATRIX™ adjuvant Lymphocytes Microbiology Miscellaneous Phospholipids - administration & dosage Production capacity Proteins Public health Rodents Saponins - administration & dosage Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Synthetic - administration & dosage Virology |
| title | The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A15%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20utility%20of%20ISCOMATRIX%E2%84%A2%20adjuvant%20for%20dose%20reduction%20of%20antigen%20for%20vaccines%20requiring%20antibody%20responses&rft.jtitle=Vaccine&rft.au=Boyle,%20Jeff&rft.date=2007-03-30&rft.volume=25&rft.issue=14&rft.spage=2541&rft.epage=2544&rft.pages=2541-2544&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2006.12.018&rft_dat=%3Cproquest_cross%3E3379246201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1547165500&rft_id=info:pmid/17240491&rft_els_id=S0264410X0601348X&rfr_iscdi=true |